Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

NCT04728932 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04728932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04728932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2021
Completion date
November 9, 2024
Enrollment
206 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cardiogenic shock, extracorporeal membrane oxygenation complication